论文部分内容阅读
目的研究PI3K p110α蛋白在宫颈上皮内瘤变和宫颈癌中的表达及其与临床病理特征的关系。方法应用ElivisionTMSuper免疫组化法检测40例正常宫颈、31例CINⅠ、33例CINⅡ、35例CINⅢ和41例宫颈癌石蜡标本中PI3K p110α的表达,比较各组间的差别及与患者临床病理特征的关系。结果①PI3K p110α在正常宫颈、CINⅠ、CINⅡ、CINⅢ及宫颈癌中的阳性率依次为0.0%、19.4%、57.6%、65.7%、80.5%。②比较正常宫颈与CINⅠ之间(χ2=8.451,P=0.004)及CINⅠ与CINⅡ之间(χ2=9.810,P=0.002),PI3K p110α阳性率差异有统计学意义;CINⅡ组与CINⅢ组之间(χ2=0.476,P=0.490)及CINⅢ与宫颈癌之间(χ2=2.125,P=0.145)比较,随着分期的增加呈上升趋势,但差异无统计学意义。③PI3K p110α在LSIL和HSIL中的阳性率分别是19.4%和61.8%,差异有统计学意义(χ2=15.333,P=0.000),可将其视为宫颈LSIL与HSIL间的辅助鉴别指标。④PI3K p110α蛋白表达与宫颈癌临床分期、组织分化程度及有无淋巴结转移有关(P<0.05)。结论 PI3K p110α在除正常宫颈组织外的各级宫颈病变组织中均呈阳性表达,抑制其活性可能为宫颈癌的治疗提供新靶点。
Objective To study the expression of PI3K p110α protein in cervical intraepithelial neoplasia and cervical carcinoma and its relationship with clinicopathological features. Methods The expression of PI3K p110α in 40 cases of normal cervix, 31 cases of CINⅠ, 33 cases of CINⅡ, 35 cases of CINⅢ and 41 cases of cervical cancer was detected by ElivisionTMSuper immunohistochemical method. The differences between the groups and their clinicopathological features relationship. Results ① The positive rates of PI3K p110α in normal cervix, CINⅠ, CINⅡ, CINⅢ and cervical cancer were 0.0%, 19.4%, 57.6%, 65.7% and 80.5%, respectively. ② The positive rates of PI3K and p110α between the normal cervix and CINⅠ (χ2 = 8.451, P = 0.004) and between CINⅠ and CINⅡ (χ2 = 9.810, P = 0.002) were significantly different; (χ2 = 0.476, P = 0.490), and between CINⅢ and cervical cancer (χ2 = 2.125, P = 0.145). However, the difference was not statistically significant with the increase of staging. ③ The positive rates of PI3K p110α in LSIL and HSIL were 19.4% and 61.8%, respectively (χ2 = 15.333, P = 0.000), which could be regarded as auxiliary differential markers between LSIL and HSIL. ④ PI3K p110α protein expression and clinical stage of cervical cancer, histological differentiation and lymph node metastasis (P <0.05). Conclusion The PI3K p110α expression was positive in cervical lesions at all levels except normal cervical tissue. Inhibition of PI3K p110α may provide a new target for the treatment of cervical cancer.